BLAINJECTIONINJECTABLE
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
RIABNI (rituximab-arrx) by Amgen is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2020.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIABNI is a CD20-directed cytolytic monoclonal antibody approved by FDA in December 2020 as a biosimilar to the reference rituximab product. It is used to treat CD20-positive B-cell malignancies and autoimmune conditions by binding to CD20 antigen on B cells and inducing cell death. This injectable biologic is administered intravenously and represents Amgen's entry into the competitive rituximab biosimilar market.
$0.003BPart D
PeakRIABNI is at peak commercial stage with modest Part D penetration ($3M spend, 406 claims in 2023), indicating significant upside potential in a mature biosimilar market dominated by reference products and established competitors.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RIABNI offers exposure to biosimilar commercial strategy, payer negotiations, and market share competition in a mature CD20 antibody market; career growth depends on driving market penetration against established competitors and capturing share from legacy products approaching LOE. Positions are heavily weighted toward commercialization, managed care, and field sales rather than clinical or R&D.
Brand Manager
Worked on RIABNI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.